Peripartum outcomes and immune responses after SARS-CoV-2 infection in the third trimester of pregnancy.
Humans
Pregnancy
Female
COVID-19
/ immunology
Pregnancy Complications, Infectious
/ immunology
Pregnancy Trimester, Third
/ immunology
Adult
Pregnancy Outcome
Infant, Newborn
SARS-CoV-2
/ immunology
Fetal Blood
/ immunology
Peripartum Period
/ immunology
Antibodies, Viral
/ blood
Cytokines
/ blood
Obstetric Labor, Premature
/ immunology
COVID-19
Immune response
Peripartum outcomes
Pregnancy
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
30
04
2024
accepted:
18
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
SARS-CoV-2 infection in pregnant women during the third trimester resulted in overall adverse pregnancy outcomes compared to non-infected controls and a unique humoral and cellular response at delivery. In this study we aimed to assess the impact of SARS-CoV-2 infection on maternal/neonatal peripartum outcomes andimmunological profiles. In this study, we recruited 304 SARS-CoV-2 infected pregnant women and 910 SARS-CoV-2 non-infected pregnant women who were admitted for delivery. Peripartum and neonates' outcomes response to SARS-CoV-2 infection were analyzed. Furthermore, we characterized the antibody and cytokines profile in SARS-CoV-2 infected maternal blood (MB) and cord blood (CB). We also assessed routine laboratory tests and liver function tests in MB before labor. Unpaired T test, Mann-Whitney test and Spearman test were used to analyze the data. SARS-CoV-2 infected pregnant women were significantly associated with increased risk of adverse pregnancy outcomes, including preterm labor (13.8% vs. 9.5%, p = 0.033) and meconium-stained amniotic fluid (8.9% vs. 5.5%, p = 0.039). The risk of low birth weight (< 2500 g) (10.5% vs. 6.5%, p = 0.021) and Apgar score < 8 at 1-minute (9.2% vs. 5.8%, p = 0.049) significantly increased in newborns from COVID-19 positive mothers than their counterparts. Our results showed that antibodies were increased in adverse-outcome SARS-CoV-2 infected mothers and their neonates, and abnormal proportion of immune cells were detected in SARS-CoV-2 infected mothers. While the immune response showed no difference between adverse-outcome infected pregnant women and normal-outcome infected pregnant women. Thus, SARS-CoV-2 infection during the third trimester of pregnancy induced a unique humoral and cellular response at delivery. SARS-CoV-2 infection closer to delivery could incline to adverse pregnancy outcomes. Therefore, the utmost care is required for SARS-CoV-2 infected pregnant women and their newborns. The study protocol was approved by the Institutional Review Board of the First Hospital of Jilin University with the approval code number 23K170-001, and informed consent was obtained from all enrolled patients prior to sample collection.
Sections du résumé
BACKGROUND
BACKGROUND
SARS-CoV-2 infection in pregnant women during the third trimester resulted in overall adverse pregnancy outcomes compared to non-infected controls and a unique humoral and cellular response at delivery. In this study we aimed to assess the impact of SARS-CoV-2 infection on maternal/neonatal peripartum outcomes andimmunological profiles.
METHOD
METHODS
In this study, we recruited 304 SARS-CoV-2 infected pregnant women and 910 SARS-CoV-2 non-infected pregnant women who were admitted for delivery. Peripartum and neonates' outcomes response to SARS-CoV-2 infection were analyzed. Furthermore, we characterized the antibody and cytokines profile in SARS-CoV-2 infected maternal blood (MB) and cord blood (CB). We also assessed routine laboratory tests and liver function tests in MB before labor. Unpaired T test, Mann-Whitney test and Spearman test were used to analyze the data.
RESULTS
RESULTS
SARS-CoV-2 infected pregnant women were significantly associated with increased risk of adverse pregnancy outcomes, including preterm labor (13.8% vs. 9.5%, p = 0.033) and meconium-stained amniotic fluid (8.9% vs. 5.5%, p = 0.039). The risk of low birth weight (< 2500 g) (10.5% vs. 6.5%, p = 0.021) and Apgar score < 8 at 1-minute (9.2% vs. 5.8%, p = 0.049) significantly increased in newborns from COVID-19 positive mothers than their counterparts. Our results showed that antibodies were increased in adverse-outcome SARS-CoV-2 infected mothers and their neonates, and abnormal proportion of immune cells were detected in SARS-CoV-2 infected mothers. While the immune response showed no difference between adverse-outcome infected pregnant women and normal-outcome infected pregnant women. Thus, SARS-CoV-2 infection during the third trimester of pregnancy induced a unique humoral and cellular response at delivery.
CONCLUSION
CONCLUSIONS
SARS-CoV-2 infection closer to delivery could incline to adverse pregnancy outcomes. Therefore, the utmost care is required for SARS-CoV-2 infected pregnant women and their newborns.
TRIAL REGISTRATION
BACKGROUND
The study protocol was approved by the Institutional Review Board of the First Hospital of Jilin University with the approval code number 23K170-001, and informed consent was obtained from all enrolled patients prior to sample collection.
Identifiants
pubmed: 39048938
doi: 10.1186/s12884-024-06707-5
pii: 10.1186/s12884-024-06707-5
doi:
Substances chimiques
Antibodies, Viral
0
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
498Subventions
Organisme : National Natural Science Foundation of China
ID : 82001759
Organisme : Natural Science Foundation of Jilin Province
ID : YDZJ202301ZYTS438
Organisme : Natural Science Foundation of Jilin Province
ID : YDZJ202401198ZYTS
Organisme : National Key R&D Program of China
ID : 2021YFA1100701
Informations de copyright
© 2024. The Author(s).
Références
Allotey J, Fernandez S, Bonet M, Stallings E, Yap M, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320.
doi: 10.1136/bmj.m3320
pubmed: 32873575
Ferrugini CLP, Boldrini NAT, Costa FLS, Salgueiro MAOB, Coelho PDP, Miranda AE. SARS-CoV-2 infection in pregnant women assisted in a high-risk maternity hospital in Brazil: clinical aspects and obstetric outcomes. PLoS ONE. 2022;17(3):e0264901.
doi: 10.1371/journal.pone.0264901
pubmed: 35275942
pmcid: 8916667
Chinn J, Sedighim S, Kirby KA, Hohmann S, Hameed AB, Jolley J, et al. Characteristics and outcomes of women with COVID-19 giving birth at US Academic centers during the COVID-19 pandemic. JAMA Netw Open. 2021;4(8):e2120456.
doi: 10.1001/jamanetworkopen.2021.20456
pubmed: 34379123
pmcid: 8358731
Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021;193(16):E540–8.
doi: 10.1503/cmaj.202604
pubmed: 33741725
pmcid: 8084555
Smith ER, Oakley E, Grandner GW, Ferguson K, Farooq F, Afshar Y, et al. Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis. BMJ Global Health. 2023;8(1):e009495.
doi: 10.1136/bmjgh-2022-009495
pubmed: 36646475
Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, et al. SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(38):1355–9.
doi: 10.15585/mmwr.mm6938e2
pubmed: 32970660
pmcid: 7727498
Lokken EM, Walker CL, Delaney S, Kachikis A, Kretzer NM, Erickson A, et al. Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington State. Am J Obstet Gynecol. 2020;223(6):911.
Metz TD, Clifton RG, Hughes BL, Sandoval GJ, Grobman WA, Saade GR, et al. Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from Obstetric complications. JAMA. 2022;327(8):748–59.
doi: 10.1001/jama.2022.1190
pubmed: 35129581
Garcia-Flores V, Romero R, Xu Y, Theis KR, Arenas-Hernandez M, Miller D et al. Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2. Nature Communications 2022 2022/01/18;13(1):320.
Raschetti R, Vivanti AJ, Vauloup-Fellous C, Loi B, Benachi A, De Luca D. Synthesis and systematic review of reported neonatal SARS-CoV-2 infections. Nat Commun. 2020;11(1):5164.
doi: 10.1038/s41467-020-18982-9
pubmed: 33060565
pmcid: 7566441
Xu T, Cheng J, Yang Z, Guan W, Zeng Z. COVID-19 focused series: diagnosis and forecast of COVID-19. J Thorac Dis. 2023;15(3):1503–5.
doi: 10.21037/jtd-23-141
pubmed: 37065563
pmcid: 10089881
Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020 2020/08/01;584(7821):463–9.
Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817–26.
doi: 10.1001/jamapediatrics.2021.1050
pubmed: 33885740
Chmielewska B, Barratt I, Townsend R, Kalafat E, van der Meulen J, Gurol-Urganci I, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. Lancet Glob Health. 2021;9(6):e759–72.
doi: 10.1016/S2214-109X(21)00079-6
pubmed: 33811827
pmcid: 8012052
Fang Y, Fang D. Mendelian randomization analysis reveals causal relationship between obstetric-related diseases and COVID-19. Virol J. 2024;21(1):73.
Farrukh L, Mumtaz A, Sana MK. How strong is the evidence that it is possible to get SARS-CoV-2 twice? A systematic review. Rev Med Virol. 2021;31(5):e2203.
doi: 10.1002/rmv.2203
pubmed: 34546605
pmcid: 7883277
Sengpiel V, Carlsson Y, Liljeqvist J-Å, Elfvin A, Fyhr I-M, Lundgren A, et al. Confirmed reinfection with SARS-CoV-2 during a pregnancy: a case report. Clin Case Rep. 2022;10(2):e05400.
doi: 10.1002/ccr3.5400
pubmed: 35223007
pmcid: 8847408
Egerup P, Fich Olsen L, Christiansen A-MH, Westergaard D, Severinsen ER, Hviid KVR, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies at delivery in women, partners, and newborns. Obstet Gynecol. 2021;137(1):49–55.
doi: 10.1097/AOG.0000000000004199
pubmed: 33116054
Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021;175(6):594–600.
doi: 10.1001/jamapediatrics.2021.0038
pubmed: 33512440
Albrecht M, Arck PC. Vertically transferred immunity in neonates: mothers, mechanisms and mediators. Front Immunol. 2020;11:555.
doi: 10.3389/fimmu.2020.00555
pubmed: 32296443
pmcid: 7136470
Vivanti AJ, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, Do Cao J, et al. Transplacental transmission of SARS-CoV-2 infection. Nat Commun. 2020;11(1):3572.
Fenizia C, Biasin M, Cetin I, Vergani P, Mileto D, Spinillo A, et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy. Nat Commun. 2020;11(1):5128.
Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible Vertical transmission of SARS-CoV-2 from an infected mother to her Newborn. JAMA. 2020;323(18):1846–8.
pubmed: 32215581
pmcid: 7099527
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–39.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.
doi: 10.1038/s41577-020-0311-8
pubmed: 32346093
pmcid: 7187672
Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–9.
doi: 10.1038/s41586-020-2588-y
pubmed: 32717743
pmcid: 7477538
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med. 2020;8(4):420–2.
Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S-Y. Pulmonary pathology of early-phase 2019 Novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15(5):700–4.
Sadowsky DW, Adams KM, Gravett MG, Witkin SS, Novy MJ. Preterm labor is induced by intraamniotic infusions of interleukin-1β and tumor necrosis factor-α but not by interleukin-6 or interleukin-8 in a nonhuman primate model. Am J Obstet Gynecol. 2006;195(6):1578–89.
doi: 10.1016/j.ajog.2006.06.072
Robertson SA, Christiaens I, Dorian CL, Zaragoza DB, Care AS, Banks AM, et al. Interleukin-6 is an essential determinant of On-Time parturition in the mouse. Endocrinology. 2010;151(8):3996–4006.
doi: 10.1210/en.2010-0063
pubmed: 20610570
Kim S, Kim H, Yim YS, Ha S, Atarashi K, Tan TG, et al. Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring. Nature. 2017;549(7673):528–32.
Jones KL, Croen LA, Yoshida CK, Heuer L, Hansen R, Zerbo O, et al. Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation. Mol Psychiatry. 2017;22(2):273–9.
Estes ML, McAllister AK. Maternal immune activation: implications for neuropsychiatric disorders. Science. 2016;353(6301):772–7.
doi: 10.1126/science.aag3194
pubmed: 27540164
pmcid: 5650490
Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol. 1994;56(5):559–64.
doi: 10.1002/jlb.56.5.559
pubmed: 7964163
Zaretsky MV, Alexander JM, Byrd W, Bawdon RE. Transfer of inflammatory cytokines across the placenta. Obstet Gynecol. 2004;103(3):546–50.
doi: 10.1097/01.AOG.0000114980.40445.83
pubmed: 14990420
Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res. 1997;42(1):1–8.
doi: 10.1203/00006450-199707000-00001
pubmed: 9212029
Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S-M, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154–5.
doi: 10.1016/j.ijid.2020.03.020
pubmed: 32179137
pmcid: 7270890
Sahu KK, Borogovac A, Cerny J. COVID-19 related immune hemolysis and thrombocytopenia. J Med Virol. 2021;93(2):1164–70.
doi: 10.1002/jmv.26402
pubmed: 32776538
Mendonça MM, da Cruz KR, Pinheiro DS, Moraes GCA, Ferreira PM, Ferreira-Neto ML, et al. Dysregulation in erythrocyte dynamics caused by SARS-CoV-2 infection: possible role in shuffling the homeostatic puzzle during COVID-19. Hematol Transfus Cell Ther. 2022;44(2):235–45.
doi: 10.1016/j.htct.2022.01.005
pubmed: 35098037
pmcid: 8786672